Meanwhile, post-translational modifications—ubiquitination, acetylation, and SUMOylation—fine-tune effector stability and activity, with dysregulation driving YAP/TAZ hyperactivation and tumor progression (Table 1). The gene discussed is YAP1; the disease is neoplasm.